Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Canopy Partners LLC

Canopy Partners LLC trimmed its position in Edwards Lifesciences Co. (NYSE:EW) by 2.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 7,476 shares of the medical research company’s stock after selling 176 shares during the period. Canopy Partners LLC’s holdings in Edwards Lifesciences were worth $553,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Norges Bank purchased a new position in shares of Edwards Lifesciences in the fourth quarter worth about $610,895,000. Jennison Associates LLC purchased a new position in Edwards Lifesciences in the 4th quarter worth approximately $555,939,000. Vanguard Group Inc. boosted its holdings in shares of Edwards Lifesciences by 10.4% during the 4th quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company’s stock worth $5,117,845,000 after purchasing an additional 6,537,494 shares during the last quarter. Assenagon Asset Management S.A. grew its position in shares of Edwards Lifesciences by 475.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock valued at $314,182,000 after purchasing an additional 3,506,886 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $213,844,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Down 4.9 %

EW stock opened at $69.39 on Monday. The firm has a market cap of $40.79 billion, a PE ratio of 9.95, a PEG ratio of 4.82 and a beta of 1.15. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $95.25. The company has a fifty day simple moving average of $71.74 and a 200 day simple moving average of $70.66. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 500 shares of the firm’s stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the sale, the vice president now directly owns 23,189 shares in the company, valued at $1,594,475.64. This trade represents a 2.11 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $67.96, for a total value of $645,620.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,189,770.56. This represents a 16.83 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 62,553 shares of company stock valued at $4,513,064 in the last three months. Company insiders own 1.29% of the company’s stock.

Wall Street Analysts Forecast Growth

EW has been the topic of several analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $85.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Canaccord Genuity Group upped their price target on Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a research note on Thursday, February 13th. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $82.00 to $90.00 in a research report on Monday, December 16th. Evercore ISI decreased their target price on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a research report on Wednesday, February 12th. Finally, Citigroup lifted their price target on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.